☆ 4.7 Article

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center

VACCINES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study

Barbara Bailly-Caille et al.

Summary: A retrospective study was conducted on patients with advanced cutaneous squamous cell carcinoma who received Cemiplimab treatment. The results showed that concurrent use of Cemiplimab and radiotherapy improves the therapeutic response and has a sustained effect even after discontinuation of the drug. Radiotherapy also provides therapeutic benefits without increasing the occurrence of adverse events.

CANCERS (2023)

添加到收藏夹

Article Oncology

First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel

Itamar Averbuch et al.

Summary: This retrospective study examined the use of PD-1 inhibitors for the treatment of locally advanced or metastatic cSCC in elderly patients with comorbidities. The overall response rate was 80.6%, with a median progression-free survival of 29.5 months. Although there were some toxicities, this treatment showed efficacy and feasibility in this patient population.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Recommendations of the International Society of Geriatric Oncology on skin cancer management in older patients

Agata Rembielak et al.

Summary: Non-melanoma skin cancer (NMSC) is increasingly common among older adults, but they are often excluded from clinical trials and effective management guidelines remain unclear. The International Society of Geriatric Oncology (SIOG) formed a task force to explore the development of practical guidelines for older patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).

JOURNAL OF GERIATRIC ONCOLOGY (2023)

添加到收藏夹

Editorial Material Oncology

Recent Progress in the Diagnosis and Treatment of Melanoma and Other Skin Cancers

Laura Pawlik et al.

CANCERS (2023)

添加到收藏夹

Article Oncology

Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients—A Comparison between Different Immunomodulating Conditions

Ofir Zavdy et al.

Cancers (2023)

添加到收藏夹

Review Dermatology

The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma

Chia Yuen Chong et al.

Summary: Non-melanoma skin cancers (NMSCs) are the most common form of skin cancer worldwide. The global incidence of cutaneous squamous cell carcinoma (CSCC) is rising, with an estimated 2.4 million cases diagnosed in 2019. Immunotherapy, particularly PD-1-targeting drugs, has revolutionized the treatment paradigm for advanced CSCC and is now recognized as the standard of care for first-line systemic therapy, offering a response rate of approximately 50% and significant improvement in quality of life.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2023)

添加到收藏夹

Article

Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center

E. Ríos-Viñuela et al.

Actas Dermo-Sifiliograficas (2022)

添加到收藏夹

Article Oncology

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma

Paolo A. Ascierto et al.

Summary: Non-melanoma skin cancer, including basal cell carcinoma and cutaneous squamous cell carcinoma, can progress to advanced and metastatic disease in rare cases. Immunotherapy, particularly anti-PD-1 therapy, has shown promising results in the treatment of advanced NMSC, with durable responses and good tolerability. Further clinical trials and investigations are needed to improve outcomes in NMSC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry

Maximilian Haist et al.

Summary: Cutaneous squamous cell carcinoma is a common malignancy with poor survival outcomes in advanced stages. Checkpoint inhibitor therapy has demonstrated high response rates, but can result in shorter overall survival in certain patient populations. Notably, the therapy was well tolerated with few discontinuations due to toxicity.

CANCERS (2022)

添加到收藏夹

Review Medicine, General & Internal

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Enrico Zelin et al.

Summary: The review discusses potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs and analyzes the role of immunotherapy in special populations. While promising, definitive and cost-effective biomarkers for predicting response in NMSCs treated with ICIs are still lacking, requiring further validation in larger cohorts.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Meeting Abstract Oncology

Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

M. R. Migden et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting

G. Rabinowits et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

Alice Baggi et al.

Summary: A retrospective observational study in Italy evaluated the clinical outcomes of patients with advanced cSCC treated with cemiplimab. The study showed comparable safety and effectiveness results to clinical trials, and identified some clinical and biochemical factors potentially associated with response to cemiplimab.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy

Sabino Strippoli et al.

Summary: In a cohort study of 30 non-selected CSCC patients treated with cemiplimab, a 76.7% response rate was observed with 30% complete responses. Higher response rates were seen in patients with head and neck primary tumors and hemoglobin level >12 g/dl. The treatment was well tolerated with fatigue and skin toxicity being the most common adverse events.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma

Julie Valentin et al.

Summary: In this study, 22 patients with a median age of 83 [55-93] were evaluated for the safety of cemiplimab in daily practice. 77% of patients experienced 24 adverse events, with 45% being serious adverse events (SAEs) grade >= 3. One patient had a SAE grade 5 (myositis). 41% of patients discontinued treatment definitively due to adverse events. After a median follow-up of eleven months [1-22], 32% had an objective response, 47% had controlled disease, and 35% experienced progression. The safety profile observed in this cohort was worse than in phase II trials, with more treatment discontinuations due to cemiplimab toxicity.

JOURNAL OF GERIATRIC ONCOLOGY (2021)

添加到收藏夹

Letter Dermatology

Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department

T. Guillaume et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Oncology

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma

Michael R. Migden et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Cutaneous squamous cell carcinoma in the organ transplant recipient

Kristin Bibee et al.

ORAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Danny Rischin et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Meeting Abstract Oncology

Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience

C. Hober et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study

Martin Salzmann et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Geriatrics & Gerontology

Using Implementation Science to Promote the Use of the G8 Screening Tool in Geriatric Oncology

Pauline Gulasingam et al.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2019)

添加到收藏夹

Review Otorhinolaryngology

Knowing the tumour microenvironment to optimise immunotherapy

M. C. Merlano et al.

ACTA OTORHINOLARYNGOLOGICA ITALICA (2019)

添加到收藏夹

Article Dermatology

Guidelines of care for the management of cutaneous squamous cell carcinoma

Murad Alam et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

M. R. Migden et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Geriatrics & Gerontology

Frailty Consensus: A Call to Action

John E. Morley et al.

JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.